CAMBRIDGE, UK — Pascal Soriot has set an ambitious $80 billion revenue target for AstraZeneca by 2030. But he’s not stopping there.
At the drugmaker’s Discovery Centre in Cambridge, UK, the CEO, self-assured as ever, underscored his vision for “long-term growth” by centering certain drug modalities that could be less vulnerable to generic and biosimilar competition.
As part of the company’s investor day, investors and media were invited on small-group tours of the site, which opened its doors in late 2021. Although the facility’s lab area was off limits to guests, scientists could be seen staging R&D work through glass walls.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.